- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/00 - Antineoplastic agents
Patent holdings for IPC class A61P 35/00
Total number of patents in this class: 101142
10-year publication summary
|
3433
|
3520
|
5622
|
7793
|
8492
|
9333
|
10318
|
10396
|
9760
|
640
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11276 |
1032 |
| The Regents of the University of California | 19503 |
814 |
| F. Hoffmann-La Roche AG | 7938 |
747 |
| Genentech, Inc. | 3867 |
738 |
| Bristol-myers Squibb Company | 4865 |
675 |
| Dana-Farber Cancer Institute, Inc. | 2536 |
631 |
| Board of Regents, The University of Texas System | 5613 |
547 |
| Merck Patent GmbH | 5845 |
545 |
| AstraZeneca AB | 2956 |
528 |
| Memorial Sloan-Kettering Cancer Center | 1889 |
479 |
| The Johns Hopkins University | 5529 |
452 |
| Janssen Pharmaceutica N.V. | 3615 |
442 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2832 |
425 |
| Amgen Inc. | 3900 |
424 |
| Centre National de La Recherche Scientifique | 10091 |
417 |
| Incyte Corporation | 962 |
413 |
| Bayer Pharma AG | 1085 |
410 |
| Hoffmann-La Roche Inc. | 3262 |
406 |
| Pfizer Inc. | 3371 |
404 |
| Takeda Pharmaceutical Company Limited | 2945 |
404 |
| Other owners | 90209 |